NASDAQ: CAPR Corporate & Investor Presentation December 2020 - Capricor Therapeutics, Inc.
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Corporate & Investor Presentation December 2020 NASDAQ: CAPR Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside
Forward-Looking Statements
Statements in this presentation regarding the efficacy, safety, and intended utilization of Capricor's
product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical
trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and
clinical trials; regulatory developments involving products, including the ability to obtain regulatory
approvals or otherwise bring products to market; plans regarding current and future collaborative
activities and the ownership of commercial rights; scope, duration, validity and enforceability of
intellectual property rights; future royalty streams, revenue projections; expectations with respect to
the expected use of proceeds from the recently completed offerings and the anticipated effects of the
offerings, and any other statements about Capricor's management team's future expectations, beliefs,
goals, plans or prospects constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact
(including statements containing the words "believes," "plans," "could," "anticipates," "expects,"
"estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that could cause actual results
or events to differ materially from those indicated by such forward-looking statements. More
information about these and other risks that may impact Capricor's business is set forth in Capricor's
Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and
Exchange Commission on March 27, 2020 and in our Quarterly Report on Form 10-Q for the quarter
ended September 30, 2020 as filed with the Securities and Exchange Commission on November 13,
2020. All forward-looking statements in this press release are based on information available to
Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking
statements.
CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s
exosome-based candidates have been approved for clinical investigation.
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 2
Corporate Summary
• Cell and exosome-based platform therapeutics company
NASDAQ
• Two products with novel approaches to neuromuscular, infectious, Ticker: CAPR
inflammatory and cardiovascular diseases
Cash (9/30/20) 1
Cell Therapy Exosomes Platform $35.3 million
Cardiosphere-derived cells (CAP-1002) Engineered Exosomes & CDC-Exosomes
Common shares1
20.4 million
• Late-stage clinical development in DMD and rapidly progressing
program in COVID-19 Non-Dilutive Capital
$45 million
• Expanding engineered exosome platform delivering RNA
External Collaborators
• Over 100 publications from multiple institutions worldwide on both US Army
platforms with extensive in-vivo and clinical data US Department of Defense
Stephen Gould, Ph.D.
• Efficient use of capital including non-dilutive sources Cedars-Sinai Medical Center
• Experienced management team
1As of 11/13/20 as reported in Form 10Q
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 3
Capricor’s Product Pipeline
Target Development Phase
Candidate Indications Discovery Preclinical Phase I Phase II Phase III Status
CAP-1002 Duchenne Muscular
Positive Phase II reported
(allogeneic CDCs) Dystrophy
CAP-1002
COVID-19 Actively recruiting patients
(allogeneic CDCs)
Exosome mRNA Vaccine
SARS-CoV-2 In development
Tripartite mRNA design
Exosome VLP Display
Vaccine SARS-CoV-2 In development
4-part antigen design
CDC-Exosomes Duchenne Muscular
IND submitted
(allogeneic CDC-XOs) Dystrophy
Engineered Exosomes
Evaluating Platform
(RNA delivery)
ASTEX-Exosomes
(engineered fibroblast- Evaluating Platform
derived XOs)
Cell Therapy Exosome Platform
Capricor's exosomes technology has not yet been approved for clinical investigation.
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 4
Exosome
Platform
Overview
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside
Exosomes Platform
Potential New Class of Therapeutics
Extracellular vesicles - term for cell-derived
vesicles, including exosomes
Nanometer-sized lipid-bilayer vesicles
Rich in RNAs and proteins
Secreted by nearly all cell types
Cell signaling modality
Potential for broad therapeutic applicability
IP: Exclusive world-wide license agreement
with Cedars-Sinai Medical Center for IP
rights related to the exosomes technology
originating from cardiosphere-derived cells
(CDCs)
Kidney International (2010) 78, 838–848
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 6
From Discovery to Platform Development
Publications
covering our
technology have
been published by
us or our
collaborators in
multiple peer-
reviewed journals.
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 7
Capricor’s Potential Solutions to
Complex Problems
Problems Possible Solutions
1. Gene therapy using viral delivery Exosomes:
(AAV) ‒ nature’s delivery vehicle
‒ Immune response
‒ low immunogenicity
2. Delivery of RNAs
‒ Uptake to render biologic relevance ‒ can deliver contents to the cell
without integration
‒ Therapeutic development slow
3. Synthetic nanoparticles are ‒ can be targeted (tropism)
untargeted delivery vehicles
‒ can be lyophilized for ease of
handling
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 8
Exosomes: Building a New Class
of Therapeutics
Infectious Oncology Ongoing Collaborations
Diseases • Stephen Gould, Ph.D.
Vaccines &
• US Army Institute for Surgical Research
mRNA and VLP targeted
• US Department of Defense
vaccine delivery
approaches therapeutics • Cedars-Sinai Medical Center
Neuromuscular
Monogenic Goals
& Inflammatory
Diseases • Drive innovation and research through
Protein or collaborations
mRNA
mRNA • Scale and partner
therapeutics
therapeutics • Expand and exploit platform and IP
through partnerships
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 9
Engineered Exosome
Platform
mRNA and VLP
Exosome-based Vaccines
10Exosomes Target Cargo Directly to the Cell
‒ Exosomes serve as a natural signaling
system
‒ CD-9, CD-81 and CD-63 are surface
markers of exosomes and can serve as
targeting molecules for effective delivery
to cells and confirmation of exosome
loading
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 11Coronavirus Structure
Unique Protein Visualization
‒ Other mRNA vaccines in
development are targeting
the spike “S” protein solely
‒ Capricor’s exosome
platform vaccine addresses
all 4 proteins: E,M,N,S
4 antigens likely to yield increased
protective response
Two unique vaccine approaches utilizing exosomes:
(1) mRNA & (2) VLP vaccines
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 12Capricor’s Exosome-Based Vaccines
Approach is Distinctive
Exosome-based approach
‒ Allows for specificity in cellular targeting
‒ Innovative technology - yet is well characterized
Unique 4-antigen approach
‒ Potentially confers greater immunity by targeting all 4 antigens
Exosomes potentially superior to liposomes
‒ Not recognized as foreign by immune system
‒ Deliver payload directly to cytoplasm
‒ Superior targeting permits lower doses
‒ Target both T and B cells – allows for immediate activity and long-term memory
Two differentiated vaccine approaches under development
‒ Platform permits accelerated innovation of both mRNA and VLP vaccines
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 13Exosome mRNA Vaccine
Exosome-based mRNA vaccine can have the following potential benefits:
‒ Delivering payload directly to cytoplasm
‒ Superior targeting may permit lower doses
‒ Exosome based mRNA vaccine will have all 4 proteins for better immune response
‒ Exosomes address the delivery problem by targeting cells of interest
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 14Exosome-mRNA Vaccine Preclinical Results
Key findings:
• Development of safe, non-toxic exosome
formulation capable of delivering functional
mRNA in vitro and in vivo
• Creation of a multiplexed exosome-RNA vaccine
that expresses viral antigens engineered to
induce cellular immunity and antibody responses
to multiple proteins of SARS-CoV-2
• Validation that an exosome mRNA vaccine can
induce:
• Persistent cellular immune responses to
the SARS-CoV-2 N and S proteins
• Moderate but sustained antibody
responses to the SARS-CoV-2 N and S
proteins
• Following a low-dose immunization protocol, no
evidence of vaccine-induced adverse events
Exosome-mRNA vaccine
demonstrates
long lasting cellular
immunity
Results from bioRxiv, Gould Nov. 2020
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 15Exosome-mRNA Vaccine Preclinical Results
Exosome-mRNA
vaccine demonstrates
long lasting humoral
immunity
Results from bioRxiv, Gould Nov. 2020
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 16Exosome VLP: Display Vaccine Approach*
Capricor’s exosome
platform vaccine addresses
all 4 proteins: N,S,M,E
*Makes use of highly optimized expression system developed by the Gould lab
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 17CAP-1002 Cell Therapy Overview
Capricor’s CAP-1002 Technology
CAP-1002 is a biologic consisting of allogeneic
cardiosphere-derived cells (CDCs)
• Manufactured from donated heart muscle
• Does not act by “stemness” - the cells do not engraft
into host tissue
• MOA: cells secrete exosomes:
‒ Contain miRNAs, non-coding RNAs and proteins
‒ Internalized by target cells
‒ Stimulate diverse and lasting changes in cellular
behavior
‒ 3 known miRNAs drive CAP-1002 potency
• CAP-1002 has been investigated in multiple
independent clinical trials and approximately 200
human subjects to date
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 19Mechanism of Action:
Defined in “Stem Cell Reports”
phospho-Akt HO-1 GCLC cat. sub.
Oxidative
Nrf2 (cytoplasmic)
Stress catalase SOD-2
Nrf2 (nuclear)
phospho-IkB CD68+ macrophages
Inflammation NF-kB p65 (nuclear)
MCP1 CD3+ T cells
collagen I
Fibrosis
collagen III
mitochondrial DNA copy number RESTORED mitochondrial ultrastructure
Cellular Energy NORMALIZED deficient respiratory capacity
level of respiratory chain subunits of isolated mitochondria
Ki67+ cardiomyocytes
Muscle Cell
Generation Aurora B cardiomyocytes
*CDCs have been the subject of >100 peer-reviewed papers since 2007.
Aminzadeh et al. Stem Cell Reports. 2018.
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 20CAP-1002
Duchenne
Muscular
Dystrophy
Program
21DMD: Lack of Dystrophin Predisposes
Muscle to Damage
• Dystrophin is a structural protein
located within the muscle fiber membrane
Whole Muscle
• Acts both as a cushion and a kind of glue Tissue
• Without dystrophin, muscles are unable to
function properly, suffer progressive damage and Muscle-Fiber
eventually die Membrane
• Much of the muscle injury that occurs in
dystrophin-deficiency is attributable to
secondary damage caused by inflammation
Dystrophin
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 22Trajectory of CDCs in DMD (Preclinical Data)
• Hypothesis: CDCs to treat cardiomyopathy
• Left ventricular ejection fraction markedly improved vs. control
– PCapricor’s Addressable DMD Population
CAPRICOR’s
Targeted Patient
Population
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 24Competitive Landscape for DMD
Options Challenges CAP-1002 Benefits
Exon Skipping – treats a small
portion of the DMD population Immunomodulatory
Exon Skipping
Gene therapy – potential safety Anti-fibrotic
Gene therapy risks
Pro-regenerative
NF-kB NF-kB inhibition may not be
enough Cellular Energy
Steroids
Steroids have adverse side-
effects
We believe CAP-1002 may be used synergistically with other therapeutics aimed to
treat DMD
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 25Primary Efficacy Endpoint
Performance of the Upper Limb (PUL: v1.2) to Assess Skeletal Muscle
PUL v.2.0:
• 3-point response scale - more robust and reproducible than v1.2
• Compensatory strategies allowed to achieve tasks (not allowed in v1.2)
• v2.0: better able to detect change at 12 months at all levels of ability*
*Mayhew et al, 2019; Pane et al, 2018.
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 26Capricor’s Regulatory Designations - DMD
GOAL OF FDA’S RMAT DESIGNATION
To facilitate efficient development and expedite review of a drug
Similar to breakthrough therapy designation:
• RMAT provides benefits that include more frequent meetings with FDA to discuss the development
plan for the product candidate
• Eligibility for rolling review and priority review
Products may also be eligible for accelerated approval
• On the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical
benefit
• Reliance upon data obtained from a meaningful number of sites
Rare Pediatric
Disease Designation
RMAT Designation
Orphan
Drug Designation
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 27HOPE-Duchenne Focused on Older
DMD Patients
• Phase I/II study: 25 patients, randomized and open-label
• One-time, multi-vessel, intracoronary delivery of cells
• HOPE population were all on stable corticosteroids
• Very limited options for this patient population
RESULTS
• Reduction in cardiac scar at 6 and 12 months measured by
MRI
• Improvement in cardiac function (systolic wall thickening) at
6 and 12 months
• Improvements shown in PUL (mid + distal)
– Best improvement shown within the first 3 months
• Study published in February 2019 in Journal of Neurology
https://n.neurology.org/content/92/8/e866.
Study funded with the support of CIRM
https://clinicaltrials.gov/ct2/show/NCT02485938.
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 28HOPE-Duchenne: Phase I/II Results
Reduced Cardiac Scar and Improved PUL
Scar
R.G. Victor et al., AHA LBCT 2017; M. Taylor et al., submitted
*p-values are based on absolute change from baseline
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 29HOPE-2
Phase II Clinical Study
30HOPE-2 Clinical Trial
• Design: Phase II, randomized, double-blind, placebo-controlled trial
in participants with DMD and reduced skeletal muscle function
• Objective: Evaluate safety and efficacy of CAP-1002
• Dosing Regimen: 150M cells delivered
intravenously every 3 months
• Sites: 9 sites (USA)
• Data: ITT population - 20 subjects
• Demographics
‒ Mean age: 14.3 years
‒ All patients were on corticosteroids
‒ ~ 80% of patients were non-ambulant
https://www.clinicaltrials.gov/ct2/show/study/NCT03406780.
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 31Clinically Meaningful Changes Observed in PUL 2.0
(Shoulder + Mid + Distal)
PUL 2.0 (full) PUL 2.0 (full)
MONTH 12/ET
MONTH 12/ET
Mean Change from Baseline +/- SEM
Mean Change from Baseline +/- SEM
4
0 CAP-1002
PLACEBO 2
-1 0
-2
-2
improvement -4
-3
-6 p=0.0201
(t test; two-tailed)
-4 -8
02
O
p=0.0532
EB
10
-5
C
P-
A
A
PL
C
Δ2.4 points in CAP-1002 vs. placebo at 12-months
Comparisons treated vs. placebo using mixed model repeated measures ANOVA
with covariates at baseline, 3 months, 6 months, 9 months and 12 months
P-values are nominal values unadjusted for multiple testing
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 32Cardiac Improvements Observed
Ejection Fraction %, CK-MB, LV-ESV and LV-EDV
LV EF (%) LV ES Volume, Indexed, ml/m2
MONTH 12/ET MONTH 12/ET
Mean Change from Baseline +/- SEM
Mean Change from Baseline +/- SEM
CAP-1002 CAP-1002
1 4
PLACEBO PLACEBO
Has been used as a
0 2 surrogate endpoint for
approval in adult heart
failure
-1 improvement 0
improvement
-2 -2
p=0.0042 p=0.0122
-3 -4
LV ED Volume, Indexed, ml/m2
Creatine Kinase MB/Total Creatine Kinase (%)
Change From Baseline MONTH 12/ET
Mean Change from Baseline +/- SEM
CAP-1002
4 ✱✱✱ 5
CAP-1002 PLACEBO
3
Placebo 0
2
% CK-MB
Enzyme associated 1 improvement
with breakdown -5
of cardiac muscle 0
cells improvement
-1 -10
p=0.006
p=0.0699
-2
Month 12 -15
Comparisons treated vs. placebo using mixed model repeated measures ANOVA
Visit with covariates at baseline, 3 months, 6 months, 9 months and 12 months
P-values are nominal values unadjusted for multiple testing
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 33HOPE-2 Safety Results
• A total of 69 infusions (CAP-1002 or placebo) were performed in
HOPE-2
• Generally safe and well tolerated throughout the study
• With the exception of hypersensitivity reactions, no safety
signals were identified
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 34Conclusions and Future Directions
Conclusions: Moving Forward:
‒ First placebo-controlled trial ‒ FDA continues to encourage us to
showing upper limb functional conduct a Phase III study; we continue
improvements in non-ambulant to discuss next steps and pathway to
DMD patients approval
‒ Directionally consistent ‒ Engaged Lonza (global CMO) for scale-
improvements in strength, up of manufacturing of CAP-1002
respiratory and cardiac endpoints ‒ HOPE-2 Open label extension trial
‒ First ever study in DMD that underway
correlates cardiac functional
stabilization with reduction of a
biomarker of myocardial cell
damage
‒ Consistent results shown pre-
clinically, Phase I/II and Phase II
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 35World-Class DMD Advisory Board
Craig McDonald, M.D. (National PI) University of California at Davis (USA)
Michelle Eagle, Ph.D., M.Sc., MCSP Atom International Ltd (UK)
Richard Finkel, M.D. Nemours Children's Hospital (USA)
Pat Furlong Parent Project Muscular Dystrophy (USA)
Kan Hor, M.D. Nationwide Children's Hospital (USA)
Cincinnati Children's Hospital Medical Center
John Jefferies, M.D.
(USA)
Oscar Henry Mayer, M.D. Children's Hospital of Philadelphia (USA)
Eugenio Mercuri, M.D., Ph.D. Catholic University of the Sacred Heart (Italy)
Francesco Muntoni, M.D. University College London (UK)
Thomas Voit, M.D. University College London (UK)
Lee Sweeney, Ph.D. University of Florida (USA)
Cincinnati Children's Hospital Medical Center
Michael Taylor, M.D., Ph.D.
(USA)
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 36CAP-1002
Cell Therapy Overview
for COVID-19
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 37CAP-1002 Targets Severe Cases of COVID-19 Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 38
Immunomodulatory Effects of CAP-1002
CDCs: Cardiosphere-derived cells
Macrophages Proinflammatory Systemic Inflammation 1. Cardiac inflammation
Cytokines 2. Lung inflammation
Effector T-cells 3. Cardiomyocyte death
Multiorgan dysfunction 4. Cardiac dysfunction
IFN-γ, TNFα, IL-1β,
IL-6, IL-8, CXCL10, 5. Skeletal muscle injury
CCL2, CCL3, CCL5 6. Tissue Fibrosis
CDCs: Mechanism of Action CDCs: Pro-inflammatory cellular CDCs: Efficacy (Pre-clinical and Clinical)
targets
1. Cardiomyogenesis 1. Myocardial ischemia (CADUCEUS, Phase I/II ALLSTAR,
2. Cardiomyocyte survival 1. Enhanced cell debris DYNAMIC Phase IIa)
3. Anti-inflammatory 2. Decreased TNFα, IL-1β, CCL5 2. Myocarditis
4. Immunomodulatory production 3. Muscular dystrophy (HOPE-Duchenne, HOPE-2)
5. Angiogenic 3. Increased levels of IL-10 by 4. Heart failure with preserved ejection fraction (REGRESS,
6. Anti-fibrotic macrophages Phase I)
5. Senescence
6. Non-ischemic dilated cardiomyopathy
7. Pulmonary arterial hypertension (ALPHA, Phase I)
Published https://link.springer.com/content/pdf/10.1007/s00395-020-0795-1.pdf
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 39CAP-1002: COVID-19 Program
Compassionate Use Data
Six critical COVID-19 patients with ARDS
Published in Basic Research in Cardiology*
‒ Treated at Cedars-Sinai Medical Center in Los Angeles, CA
‒ Received intravenous infusions of 150 million cells of CAP-1002
Results:
‒ Within 1-4 days following infusion
‒ 4 of 5 patients no longer required ventilator support
Improved biomarkers:
‒ Ferritin, absolute lymphocyte count and CRP
No adverse events related to the administration of CAP-1002 were observed
*Published https://link.springer.com/content/pdf/10.1007/s00395-020-0795-1.pdf
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 40CAP-1002: COVID-19 Program
Phase II Trial Underway
‒ INSPIRE: Phase II, randomized, double-blind, placebo-controlled trial
‒ Aim: to treat up to 60 patients in the US
‒ Study enrolling patients who have a confirmed diagnosis of SARS-CoV-2 and require
supplemental oxygen (severe to critical)
‒ Patient participation will be a maximum of 13 weeks from screening
‒ Trial actively recruiting subjects
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 41Targeted Milestones into 2021
Cell Therapy (CAP-1002) Technology
1H 2021: Plan to publish HOPE-2 final results
1H 2021: Plan to complete enrollment in INSPIRE study
1H 2021: Plan to announce results from INSPIRE study
2021: Continue to work with FDA on next steps in pathway forward for DMD
2021: Continue to pursue partnership opportunities for DMD program
Engineered Exosomes Platform Technology
1Q 2021: Plan to meet with FDA in PRE-IND meeting for mRNA vaccine
1H 2021: Plan to publish preclinical data from exosomes technology
1H 2021: Plan to announce pipeline expansion for engineered exosome program
2021: Plan to announce updates on vaccine program for COVID-19
2021: Continue to pursue grant funding activities
2021: Continue to pursue partnership opportunities
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 42World-Class
Facilities and Capricor’s Research, Development and Manufacturing facilities are
located in the Cedars-Sinai Medical Center in Los Angeles, California
Infrastructure Capricor has access to core research facilities
43Senior Leadership Team
Linda Marbán, Ph.D. Stephen Gould, Ph.D.
Chief Executive Officer, Co-founder and Director Executive Consultant
Dr. Gould is a Professor of Biological Chemistry at Johns Hopkins
Dr. Marbán has over 25 years of experience in the biotechnology
University and an internationally recognized exosome expert
industry
who brings an unparalleled understanding of exosome
Been with Capricor since 2005 and CEO since 2010.
engineering to Capricor.
Previous experience includes Excigen, Inc. where she was
Dr. Gould is co-Founder and acting President of the American
responsible for business development and operations.
Society for Exosomes and Microvesicles (ASEMV).
Dr. Marbán began her career in academic science at the
Dr. Gould’s team was the first to reveal the mechanistic link
Cleveland Clinic Foundation working on the biophysical
between exosome biogenesis and virus budding, the first to
properties of cardiac muscle and continued to a postdoctoral
identify mechanisms of exosome engineering and the first to
fellowship at Johns Hopkins University.
develop an exosome-based cancer therapeutic.
Dr. Marbán earned a Ph.D. from Case Western Reserve University
Dr. Gould has published numerous research articles and several
in cardiac physiology.
book chapters, received numerous public and private research
grants and served on an array of NIH and other grant review
Karen Krasney, J.D. panels.
Executive Vice President & General Counsel
Ms. Krasney’s has over 40 years of experience in domestic and
international corporate and business law, as well as litigation.
Ms. Krasney served as legal counsel of Biosensors International Sudhir Borgonha, M.D., M.B.A.
Group Ltd., a multinational medical device company. Vice President of Clinical Development
Ms. Krasney received her Bachelor of Arts degree from the Dr. Borgonha previously served as Director of Translational
University of California, Los Angeles and her Juris Doctorate from Medicine at the Fanconi Anemia Research Fund, where he
the University of Southern California. led efforts to propel a spectrum of approaches including
gene therapy to treat cancer in rare diseases. Prior to that,
he was the Medical Director of Strand Genomics, where he
oversaw development of new technologies such as the
liquid biopsy and customized cancer panels, while he
AJ Bergmann, M.B.A. oversaw clinical reporting for over 5,000 patients a year.
Chief Financial Officer Dr. Borgonha was a co-founder of Angstrom Medica
Mr. Bergmann has worked in the finance industry for over a (Acquired by Pioneer Surgical), a biomaterials science
decade. company. He is also a co-founder of ten3T, a
Mr. Bergmann joined Capricor in 2011 and coordinated the remote cardiac monitoring company.
Company’s reverse merger, uplisting to NASDAQ and public Dr. Borgonha is a graduate of St. John’s Medical
financings yielding over $85 million to date. College, Bangalore and the Sloan School of Management
Mr. Bergmann graduated from Providence College and has a at MIT.
M.B.A. from the University of Southern California’s Marshall
School of Business.
Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside 44You can also read
